Key facts
- This page summarizes Heather Preston's Form 4 filing for Fusion Pharmaceuticals Inc..
- 1 reported transaction and 1 derivative row are listed below.
- Accepted by SEC: 14 Jun 2023, 17:10.
Heather Preston - 14 Jun 2023 Form 4 Insider Report for Fusion Pharmaceuticals Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 14 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 14 Jun 2023, 17:10:42 UTC
- Prior SEC filing
- 02 Dec 2022
- Next SEC filing
- 09 Aug 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/Maria Stahl as Attorney-in-Fact for Heather Preston
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Heather Preston filed Form 4 for Fusion Pharmaceuticals Inc. on 14 Jun 2023.
Change
- Previous filing in this sequence was filed on 02 Dec 2022.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
FUSN
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +17,000
- Change %
- Price
- $0.000000
- Shares after
- 17,000
- Date
- 14 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 17,000
- Exercise price
- $4.64
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc.